Chart: Amplify: A "De-Risk" Approval?
This article was originally published in The Gray Sheet
Executive Summary
If FDA does approve Amplify, it is not clear that the decision will immediately add a significant amount of new sales for Medtronic, but it could help relieve some pressure on the firm's spine biologics franchise, which is under scrutiny on various fronts.